The Dermatophytic Onychomycosis Therapeutics Market is to be driven by an influx of IOMT, reaching US$ 10.30 Bn between

Posted by Archit Sanjay on July 27th, 2022

Presence and availability of a large clinical pipeline with reference to therapeutic approaches based on dermatophytic onychomycosis treatment are set to drive market growth over the coming years. According to the European Commission, more than one fifth, i.e., 20.3% of the population in EU-27 countries was aged 65 and over in 2020.

According to WHO, approximately, 80% to 85% of onychomycosis occurs in patients aged above 50 years. High prevalence of age-related disease incidence has led to an increase in the demand for biologics for therapeutic induction for dermatophytic onychomycosis treatment.

Furthermore, social conditions such as poverty, race, and social groups possess an extremely varied rate of occurrence of onychomycosis. These social disparities, together with the presence of a large populace under poverty, is a chief driver of the growth of onychomycosis.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/5840

Company Profiles:

  • Bausch Health
  • Galderma S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Moberg Pharma AB
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Medimetriks Pharmaceuticals, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical industries Ltd.
  • Cardinal Health Inc.
  • Viatris Inc.
  • Almirall, S.A

dermatophytic-onychomycosis-therapeutics-market

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/5840

Key Takeaways from Market Study

  • By treatment type, drugs are expected to hold 74.8% market value share by the end of 2032, primarily due to rising activities by key players in the drug development biosphere.
  • Distal subungual onychomycosis, by indication, is leading with 78.3% market share in 2021, owing to it being a common factor of occurrence associated with age.
  • The male segment, by gender, is leading with 61.7% market share in 2021, Males are reported to be more susceptible to onychomycosis with the most probable associated hypothesis being occupational factors as well as lower treatment compliance.
  • Age group between 18-39 years is expected to hold more than half of the market value share by the end of 2032.
  • Retail sales dominated the end user segments with a share of around 56.2% in 2021.
  • By region, North America is the leading region with an expected value share of 48.4% by 2032.

Rising geriatric population and high prevalence of onychomycosis in the elderly age group are set drive dermatophytic onychomycosis therapeutics,” says an analyst of Persistence Market Research.

Market Competition

Key market players such as Bausch Health and Dr. Reddy’s Laboratories, amongst others, are involved in research activities in the life sciences sphere. These key players also imbibe the strategy of partnerships and strategic collaborations to expand their geographical product footprint and drive sales is emerging economical territories.

  • For instance, in December 2021, Bausch Health Ortho Dermatologics the announced JUBLIA® (efinaconazole) Topical Solution, 10%, for onychomycosis treatment, which has received the American Podiatric Medical Association (APMA) seal of approval.
  • In June 2020, Dr. Reddy’s Laboratories acquired the branded generics business of Wockhardt Limited in Indiam Nepal, Sri Lanka, Bhutan, and the Maldives.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/5840

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the dermatophytic onychomycosis therapeutics market in its latest study, presenting historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the treatment type (drugs ((oral (Rx and OTC), (topical (Rx and OTC)), Laser (C02 ablative lasers, Nd:YAG lasers and dual-wave length near-infrared lasers)) and photodynamic therapy), indication (distal subungual onychomycosis , white superficial onychomycosis, proximal subungual onychomycosis, candidal onychomycosis and total dystrophic onychomycosis), gender (male and female), age group (0-18 years, 18-39 years, 40-64 years and 65 years and above), and end user (institutional sales (hospitals and dermatology clinics)) and retail sales (retail pharmacies, drug stores and mail order pharmacies & online sales)), across seven key regions of the world.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

Like it? Share it!


Archit Sanjay

About the Author

Archit Sanjay
Joined: April 12th, 2021
Articles Posted: 442

More by this author